Drug intelligence / Profile preview

TF-002

Development stage: Unknown
Modality: Small Molecules

Overview

TF-002 is a small molecule drug with mast cell stabilizing activity. It inhibits the formation of lipid rafts in mast cell membranes, which are essential for the signaling processes that trigger the release of allergic and inflammatory mediators from mast cells. By preventing this process, TF-002 may reduce symptoms associated with conditions involving abnormal mast cell activation, such as cutaneous mastocytosis[1][2].

Other names: mast cell stabilizer TF002

Beyond the preview

Go deeper on TF-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TF-002.

Explore the full profile